Bridge Biotherapeutics Inc. recently reported data for BBT-209, an endogenous G protein-coupled receptor 19 (GPCR19) agonist under development for the treatment of idiopathic pulmonary fibrosis (IPF).
Researchers from Hanmi Science Co. Ltd. presented preclinical data for the novel long-acting glucagon/GIP/GLP-1 triple agonist HM-15211, being evaluated as potential treatment of idiopathic pulmonary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results